PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.

Publication date: Jul 10, 2023

Immunohistochemistry-based protein biomarkers can provide useful prognostic information in cutaneous melanoma. The independent prognostic value of Ki-67 has been studied with variable results. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry is a useful new ancillary tool for distinguishing cutaneous nevi from melanoma; however, its prognostic value has not been well studied. We evaluated PRAME as a prognostic marker in cutaneous melanoma, compared to Ki-67. We analyzed the immunohistochemical expression of PRAME and Ki-67 in 165 melanocytic lesions, including 92 primary melanomas, 19 metastatic melanomas, and 54 melanocytic nevi using tissue microarrays. PRAME immunostaining was scored based on the percentage of positive nuclei: 0 75%. The percentage of Ki-67-positive tumor nuclei was used to calculate the proliferation index. PRAME and Ki-67 both showed significantly increased expression in melanomas compared to nevi (p 

Concepts Keywords
Cutaneous benign nevus
Immunohistochemistry cutaneous malignant melanoma
Microarrays Ki-67
tissue microarray


Type Source Name
disease MESH melanoma
pathway KEGG Melanoma
disease MESH nevi
disease MESH melanocytic nevi
disease MESH tumor

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *